|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that MCT4 is involved in energy metabolism during early pathological processes in AD, and suppression of MCT4 represents a new potential neuroprotective factor for AD.
|
31738978 |
2020 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
The NF-κB/miR-425-5p/MCT4 axis: A novel insight into diabetes-induced endothelial dysfunction.
|
31711985 |
2020 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
The NF-κB/miR-425-5p/MCT4 axis: A novel insight into diabetes-induced endothelial dysfunction.
|
31711985 |
2020 |
|
Mental deterioration
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The APP/PS1 mice began to show cognitive decline at 3 months of age and MCT4 in the hippocampus of 2- and 3-month old APP/PS1 mice was higher than that of C57 mice.
|
31738978 |
2020 |
|
Impaired cognition
|
0.010 |
Biomarker
|
disease |
BEFREE |
The APP/PS1 mice began to show cognitive decline at 3 months of age and MCT4 in the hippocampus of 2- and 3-month old APP/PS1 mice was higher than that of C57 mice.
|
31738978 |
2020 |
|
Endothelial dysfunction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The NF-κB/miR-425-5p/MCT4 axis: A novel insight into diabetes-induced endothelial dysfunction.
|
31711985 |
2020 |
|
Mild cognitive disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that MCT4 expression was elevated in the cerebrospinal fluid of patients with mild cognitive impairment.
|
31738978 |
2020 |
|
Malignant neoplasm of thyroid
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 15 targeted studies and 16 untargeted studies revealed several potential metabolite signatures of TC such as glucose, fructose, galactose, mannose, 2-keto-d-gluconic acid and rhamnose, malonic acid and inosine, cholesterol and arachidonic acid, glycosylation (immunoglobulin G [IgG] Fc-glycosylation), outer mitochondrial membrane 20 (TOMM20), monocarboxylate transporter 4 (MCT4), choline, choline derivatives, myo-/scyllo-inositol, lactate, fatty acids, several amino acids, cell membrane phospholipids, estrogen metabolites such as 16 alpha-OH E1/2-OH E1 and catechol estrogens (2-OH E1), and purine and pyrimidine metabolites, which were suggested as the TC oncometabolite.
|
30881111 |
2019 |
|
Hamartoma Syndrome, Multiple
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MCT4 upregulation was critical for fibroblast viability under CS conditions.
|
31239287 |
2019 |
|
Intestinal Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Inflammatory bowel disease (IBD) is a disorder intestinal inflammation and impaired barrier function, associated with increased epithelial expression of monocarboxylate transporter 4 (MCT4).
|
31418947 |
2019 |
|
Multiple Sclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Relevance to MS was corroborated by the strong expression of MCT-4, EMMPRIN and LDHA in perivascular macrophages in MS brains.
|
31112527 |
2019 |
|
Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analysis indicated that overall survival of osteosarcoma patients was significantly higher in the low MCT4 expression group than in the high expression group (log-rank test, P<0.001).
|
31177263 |
2019 |
|
Thyroid Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 15 targeted studies and 16 untargeted studies revealed several potential metabolite signatures of TC such as glucose, fructose, galactose, mannose, 2-keto-d-gluconic acid and rhamnose, malonic acid and inosine, cholesterol and arachidonic acid, glycosylation (immunoglobulin G [IgG] Fc-glycosylation), outer mitochondrial membrane 20 (TOMM20), monocarboxylate transporter 4 (MCT4), choline, choline derivatives, myo-/scyllo-inositol, lactate, fatty acids, several amino acids, cell membrane phospholipids, estrogen metabolites such as 16 alpha-OH E1/2-OH E1 and catechol estrogens (2-OH E1), and purine and pyrimidine metabolites, which were suggested as the TC oncometabolite.
|
30881111 |
2019 |
|
Cortical cataract
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MCT4 upregulation was critical for fibroblast viability under CS conditions.
|
31239287 |
2019 |
|
Thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 15 targeted studies and 16 untargeted studies revealed several potential metabolite signatures of TC such as glucose, fructose, galactose, mannose, 2-keto-d-gluconic acid and rhamnose, malonic acid and inosine, cholesterol and arachidonic acid, glycosylation (immunoglobulin G [IgG] Fc-glycosylation), outer mitochondrial membrane 20 (TOMM20), monocarboxylate transporter 4 (MCT4), choline, choline derivatives, myo-/scyllo-inositol, lactate, fatty acids, several amino acids, cell membrane phospholipids, estrogen metabolites such as 16 alpha-OH E1/2-OH E1 and catechol estrogens (2-OH E1), and purine and pyrimidine metabolites, which were suggested as the TC oncometabolite.
|
30881111 |
2019 |
|
Osteosarcoma of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analysis indicated that overall survival of osteosarcoma patients was significantly higher in the low MCT4 expression group than in the high expression group (log-rank test, P<0.001).
|
31177263 |
2019 |
|
Adenocarcinoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i> effects on extracellular flux via glycolysis and mitochondrial stress tests suggest that candidate compounds 3 and 9 disrupt glycolysis and OxPhos efficiently in MCT1 expressing colorectal adenocarcinoma WiDr and MCT4 expressing triple negative breast cancer MDA-MB-231 cells.
|
31040927 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MCT1 may serve as a target to treat NHL (diffuse large B cell lymphoma) patients with high MCT1/low MCT4 expressing tumours.
|
30790227 |
2019 |
|
Childhood Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analysis indicated that overall survival of osteosarcoma patients was significantly higher in the low MCT4 expression group than in the high expression group (log-rank test, P<0.001).
|
31177263 |
2019 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
In the 4NQO treated mice we detected MCT4 in foci of the basal layer undergoing transformation, and progressively in areas of carcinoma <i>in situ</i> and invasive carcinomas.
|
30211114 |
2018 |
|
Carcinoma, Transitional Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The association of MCT4 expression with molecular subtypes and outcome was determined in The Cancer Genome Atlas (TCGA) cohort and two independent cohorts of patients with urothelial carcinoma.
|
30262589 |
2018 |
|
Choriocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Valproic acid transport in the choriocarcinoma placenta cell line JEG-3 proceeds independently of the proton-dependent transporters MCT1 and MCT4.
|
30341000 |
2018 |
|
Headache
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Lactate Transporter Monocarboxylate Transporter 4 Induces Bone Pain in Head and Neck Squamous Cell Carcinoma.
|
30366393 |
2018 |
|
Hyperglycemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Experiment 2 showed lower Glut1, Gys1 and Mct4 expression and higher Mct1 expression in the hyperglycemia group, relative to the control group (p < 0.05).
|
29532970 |
2018 |
|
Bone pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Lactate Transporter Monocarboxylate Transporter 4 Induces Bone Pain in Head and Neck Squamous Cell Carcinoma.
|
30366393 |
2018 |